Lysosomal NEU1 deficiency affects amyloid precursor protein levels and amyloid-β secretion via deregulated lysosomal exocytosis

Ida Annunziata, Annette Patterson, Danielle Helton, Huimin Hu, Simon Moshiach, Elida Gomero, Ralph Nixon and Alessandra d’Azzo ()
Additional contact information
Ida Annunziata: St Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105, USA
Annette Patterson: St Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105, USA
Danielle Helton: St Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105, USA
Huimin Hu: St Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105, USA
Simon Moshiach: St Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105, USA
Elida Gomero: St Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105, USA
Ralph Nixon: Center for Dementia Research, Nathan S Kline Institute
Alessandra d’Azzo: St Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105, USA

Nature Communications, 2013, vol. 4, issue 1, 1-12

Abstract: Abstract Alzheimer’s disease (AD) belongs to a category of adult neurodegenerative conditions, which are associated with intracellular and extracellular accumulation of neurotoxic protein aggregates. Understanding how these aggregates are formed, secreted and propagated by neurons has been the subject of intensive research, but so far no preventive or curative therapy for AD is available, and clinical trials have been largely unsuccessful. Here we show that deficiency of the lysosomal sialidase NEU1 leads to the spontaneous occurrence of an AD-like amyloidogenic process in mice. This involves two consecutive events linked to NEU1 loss-of-function—accumulation and amyloidogenic processing of an oversialylated amyloid precursor protein in lysosomes, and extracellular release of Aβ peptides by excessive lysosomal exocytosis. Furthermore, cerebral injection of NEU1 in an established AD mouse model substantially reduces β-amyloid plaques. Our findings identify an additional pathway for the secretion of Aβ and define NEU1 as a potential therapeutic molecule for AD.

Date: 2013
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/ncomms3734 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:4:y:2013:i:1:d:10.1038_ncomms3734

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms3734

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().